drugset / Trial / NCT06773936
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Phase 2
Enrolling by invitation
55 enrolled
SWOG Cancer Research Network
Novartis Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?"
Timeline
- Start
- 2026-04-13
- Primary completion
- 2029-05
- Completion
- 2033-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asciminib | Unknown | — | — |
| Background | Blinatumomab | Monoclonal antibody | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | dasatinib anhydrous | Small molecule | — | — |